166 related articles for article (PubMed ID: 2345070)
1. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Fabian CJ; Molina R; Slavik M; Dahlberg S; Giri S; Stephens R
Invest New Drugs; 1990 Feb; 8(1):57-63. PubMed ID: 2345070
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
[TBL] [Abstract][Full Text] [Related]
3. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
Vukelja SJ; Baker WJ; Burris HA; Keeling JH; Von Hoff D
J Natl Cancer Inst; 1993 Sep; 85(17):1432-3. PubMed ID: 8102408
[No Abstract] [Full Text] [Related]
4. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Webster-Gandy JD; How C; Harrold K
Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
[TBL] [Abstract][Full Text] [Related]
5. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
[TBL] [Abstract][Full Text] [Related]
6. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
Drake RD; Lin WM; King M; Farrar D; Miller DS; Coleman RL
Gynecol Oncol; 2004 Aug; 94(2):320-4. PubMed ID: 15297168
[TBL] [Abstract][Full Text] [Related]
7. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
8. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Kara IO; Sahin B; Erkisi M
Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
[TBL] [Abstract][Full Text] [Related]
9. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
10. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Risum S; Langer SW
Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
[TBL] [Abstract][Full Text] [Related]
11. Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
Bellmunt J; Navarro M; Hidalgo R; Solé LA
Tumori; 1988 Jun; 74(3):329-31. PubMed ID: 3400123
[TBL] [Abstract][Full Text] [Related]
12. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome.
Vukelja SJ; Lombardo FA; James WD; Weiss RB
Ann Intern Med; 1989 Oct; 111(8):688-9. PubMed ID: 2529807
[No Abstract] [Full Text] [Related]
14. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi D; Catalano G
Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
[No Abstract] [Full Text] [Related]
15. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.
Nagore E; Insa A; Sanmartín O
Am J Clin Dermatol; 2000; 1(4):225-34. PubMed ID: 11702367
[TBL] [Abstract][Full Text] [Related]
16. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
17. Fluorouracil and palmar-plantar erythrodysesthesia.
Curran CF; Luce JK
Ann Intern Med; 1989 Nov; 111(10):858. PubMed ID: 2817635
[No Abstract] [Full Text] [Related]
18. Chemotherapy-induced palmer planter erythrodysesthesia.
Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
[TBL] [Abstract][Full Text] [Related]
19. Painful palmar and plantar erythema associated with hepatic artery infusion of 5-fluoro-2'deoxyuridine.
Neuss MN; Akwari OE; Stevenson DF; Goodwin BJ
J Natl Med Assoc; 1987 Jun; 79(6):669-71. PubMed ID: 2956430
[TBL] [Abstract][Full Text] [Related]
20. Dermatological toxicity from chemotherapy containing 5-fluorouracil.
Leo S; Tatulli C; Taveri R; Campanella GA; Carrieri G; Colucci G
J Chemother; 1994 Dec; 6(6):423-6. PubMed ID: 7699432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
